Virtus Health Limited

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Virtus Health Limited - overview

Established

1982

Location

Sydney, NSW, Australia

Primary Industry

Healthcare

About

Virtus Health Limited, based in Australia, specializes in assisted reproductive services, offering comprehensive fertility solutions to individuals and couples striving to start families through various advanced medical treatments. Founded in 1982 and headquartered in Sydney, Australia, Virtus Health Limited provides specialized assisted reproductive services. The company remains independent and does not have subsidiaries. The current CEO, Kate Munnings, leads the organization in its mission to support people facing infertility challenges.


The firm has completed a total of one deal, with the most recent deal occurring on April 6, 2022. Virtus Health specializes in assisted reproductive services, focusing on providing comprehensive support for individuals and couples aiming to create families. Their primary offerings include a range of fertility treatments, such as in vitro fertilization (IVF), advanced reproductive genetics, and reproductive pathology services. These services are designed to address various infertility challenges by utilizing advanced technologies and methodologies, with an emphasis on individualized care.


Virtus Health operates a robust network of 43 fertility clinics and seven specialist day hospitals across Australia, Ireland, Denmark, the UK, and Singapore, catering to a diverse client base that includes patients seeking fertility solutions. In the most recent financial year, Virtus Health generated revenue of AUD 242,505,678. 20 and reported an EBITDA of AUD 70,217,138. 80 for the same period.


In April 2022, BGH Capital made an offer to acquire Virtus Health at AUD 8. 00 per share, which was revised to AUD 8. 15 per share following no response from CapVest Partners. This acquisition bid may influence Virtus Health's strategic direction and growth plans.


The company aims to expand its offerings and geographic presence, although specific details on new products or services have not been disclosed.


Current Investors

BGH Capital

Primary Industry

Healthcare

Sub Industries

Hospitals, Diagnostic, Medical & Imaging Laboratories, Clinics/Outpatient Services

Website

www.virtushealth.com.au

Verticals

HealthTech

Company Stage

Mature

Total Amount Raised

Subscriber access only

Virtus Health Limited - financials

Fiscal Year EndedJun 30, 2012Jun 30, 2013Jun 30, 2014Jun 30, 2015Jun 30, 2016Jun 30, 2017Jun 30, 2018Jun 30, 2019Jun 30, 2020Jun 30, 2021
Revenue (USD)165,119,000186,581,000201,249,000233,696,000261,210,000256,518,000262,061,000---
% Revenue Growth (YoY)-13.0%7.9%16.1%11.8%(1.8%)2.2%---
EBITDA (USD)48,708,00048,942,00060,216,00062,486,00069,267,00063,298,00065,370,000---
Operating Income (USD)39,736,00035,136,00051,561,00051,581,00057,879,00050,926,00052,667,000---
Operating Margin24.1%18.8%25.6%22.1%22.2%19.9%20.1%---
% EBITDA Margin29.5%26.2%29.9%26.7%26.5%24.7%24.9%---
NET Income (USD)19,660,00010,104,00030,957,00030,441,00034,865,00030,004,00032,009,000---
% Net Margin11.9%5.4%15.4%13.0%13.3%11.7%12.2%---

Virtus Health Limited - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
Public to PrivateCompletedVirtus Health Limited-

Displaying 1 - 1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.